news
Inhibiting protein slows glioblastoma tumour growth
Researchers have discovered that inhibiting the ID1 protein slows the growth of glioblastoma tumours and reduces resistance to chemotherapy.
List view / Grid view
Cancer Research
article
A pragmatic approach to hit validation following biochemical high-throughput screening
Progressing actives from a high-throughput screen (HTS) of a target protein into suitable starting points for lead identification is fraught with pitfalls. The volume and quality of the HTS output is a function of the quality of the screening library, as well as specific properties of both the target and…
news
Cancer Research triples funding for pancreatic cancer
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The charity increased spending on pancreatic cancer research, which includes improving diagnosis and treatment, to £18 million...
news
Neurodegenerative diseases: The potential of cyclophilin inhibition
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
news
Microptosis could present an antimicrobial drug development opportunity
20 January 2016 | By Victoria White
Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
news
Researchers freeze EBV by disrupting the cell supply chain
20 January 2016 | By Victoria White
Researchers made B-cells sense they were starving by using the drug Rapamycin, enabling them to turn the senescence of EBV-infected cells on and off...
news
Regen BioPharma and NCATS to research the NR2F6 protein
20 January 2016 | By Victoria White
The collaboration will focus on identifying ligands for NR2F6 using Regen's screening methodology and the expertise and unique chemical libraries of NCATS...
news
New study finds laws of nature predict cancer evolution
19 January 2016 | By Victoria White
Researchers believe that in the future, they could predict how a cancer will grow and develop by applying natural laws to single genetic snapshots taken from a cancer...
news
Breast cancer study reveals new drug targets and combinations
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
news
UCL announces new £50 million fund to commercialise research
18 January 2016 | By Victoria White
The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies...
news
F-star and AbbVie to develop bispecific antibodies in immuno-oncology
18 January 2016 | By Victoria White
Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
news
Channel-blocker drug helps restore vision in mice with optic nerve injury
14 January 2016 | By Victoria White
Researchers were able to restore vision in mice by using gene therapy to get the nerves to regenerate and adding a channel-blocking drug to help the nerves conduct impulses...
news
Sanofi Pasteur announces support for the Human Vaccines Project
14 January 2016 | By Victoria White
The Human Vaccines Project is a research programme designed to accelerate the development of vaccines by decoding the human immune system...
news
Boehringer and Arena to advance research in psychiatric diseases
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
news
MSD acquires drug discovery company IOmet
12 January 2016 | By Victoria White
The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...